Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05955014 · ClinicalTrials.gov registry record
Data Collection Protocol for Patients With Von Hippel Lindau Disease
A clinical trial of Von Hippel-Lindau Disease, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT05955014 is a study of Von Hippel-Lindau Disease that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 125 participants, below the 2,219-participant average among 5 other Von Hippel-Lindau Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05955014, a study of Von Hippel-Lindau Disease, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
Conditions Studied
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05955014
The ClinicalTrials.gov registry entry for NCT05955014 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,219-participant average among 5 other Von Hippel-Lindau Disease trials with a reported enrollment target (94% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Hippel-Lindau Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05955014 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05955014 about?
NCT05955014 is a clinical study titled "Data Collection Protocol for Patients With Von Hippel Lindau Disease". To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
What is the current status of trial NCT05955014?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2023-08-24. Estimated completion is 2026-12-31.
What conditions does trial NCT05955014 study?
This clinical trial studies the following conditions: Von Hippel-Lindau Disease.
Who is sponsoring clinical trial NCT05955014?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05955014 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Hippel-Lindau Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RECRUITING · Phase 2
-
MyVHL: Patient Natural History Study
RECRUITING
-
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 2
-
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
ACTIVE NOT RECRUITING
-
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.